Last reviewed · How we verify

NCT04558307

Feasibility of Rapid COVID-19 Testing in Disadvantaged Populations

Completed Last updated 13 July 2021
What this trial tests

trial testing Pilot a rapid SARS-CoV-2 testing strategy in Coronavirus Disease (COVID-19) in 1,000 participants. Completed in 1 June 2021.

Timeline
3 June 2020
Primary endpoint
1 June 2021
1 June 2021

Quick facts

Lead sponsorMayo Clinic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,000
Start date3 June 2020
Primary completion1 June 2021
Estimated completion1 June 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

Eligibility, any sex, with Coronavirus Disease (COVID-19). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the feasibility of establishing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing at a federally-qualified health center (FQHC) during a global health crisis to mitigate COVID-19 disparities in socioeconomically disadvantaged populations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronavirus Disease (COVID-19)

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04558307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing